Akari Therapeutics (AKTX) Payables (2011 - 2026)

Akari Therapeutics (AKTX) has 16 years of Payables data on file, last reported at $8.7 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 34.64% year-over-year to $8.7 million; the trailing twelve-month figure through Mar 2026 stood at $8.7 million (down 34.64% YoY), and the FY2025 full-year result was $8.9 million, down 32.26% from the prior year.
• Payables retreated to $8.7 million in Q1 2026, from $8.9 million in the prior quarter.
• In the past five years, Payables ranged from a high of $13.3 million in Q1 2025 to a low of $947000.0 in Q4 2022.
• A 5-year average of $7.5 million and a median of $8.7 million in 2026 frame the typical range for Payables.
• Across the five-year window, Payables plunged 47.05% in 2022 and soared 681.93% in 2024, its largest moves.
• Tracing AKTX's Payables over 5 years: stood at $947000.0 in 2022, then jumped by 76.45% to $1.7 million in 2023, then soared by 681.93% to $13.1 million in 2024, then plunged by 32.26% to $8.9 million in 2025, then slipped by 1.82% to $8.7 million in 2026.
• Business Quant data shows AKTX's Payables at $8.7 million in Q1 2026, $8.9 million in Q4 2025, and $11.0 million in Q3 2025.